GBG Forschungs GmbH (German Breast Group)

Industry / private company


Location: Neu-Isenburg, Germany (DE) DE

ISNI: 0000000404572954

ROR: https://ror.org/03c8hnh70

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Utility of the CPS plus EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2019) Marme F, Solbach C, Michel L, Fasching P, Schneeweiss A, Blohmer JU, Rezai M, et al. Conference contribution Clinical relevance of collagen protein degradation markers C3M and C4M in the serum of breast cancer patients treated with neoadjuvant therapy in the geparquinto trial (2019) Banys-Paluchowski M, Loibl S, Witzel I, Mundhenke C, Lederer B, Solbach C, Karn T, et al. Journal article KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer (2019) Mamounas EP, Geyer CE, Huang CS, Mano MS, Loibl S, Untch M, Wolmark N, et al. Conference contribution Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Node–positive study (2019) Noske A, Möbus V, Weber K, Schmatloch S, Weichert W, Köhne CH, Solbach C, et al. Journal article Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto (2019) Laakmann E, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, Tesch H, et al. Journal article Influence of PIK3CA mutations on breast cancer proliferation, lymphocyte infiltration and clinical outcome: Pooled analysis of 484 patients from three prospective multicentre GBG trials (2019) Jank P, Loibl S, Fasching P, Karn T, Marme F, Mueller V, Schem C, et al. Conference contribution A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA) (2019) Bischoff J, Barinoff J, Mundhenke C, Bauerschlag DO, Costa SD, Herr D, Luebbe K, et al. Journal article Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer (2019) Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, et al. Journal article Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial (2019) Witzel I, Loibl S, Wirtz R, Fasching P, Denkert C, Weber K, Lück HJ, et al. Journal article AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019 (2019) Thill M, Jackisch C, Janni W, Müller V, Albert US, Bauerfeind I, Blohmer J, et al. Journal article